PeptideJournal
Guides17 min read

Peptides for Mitochondrial Health

Your mitochondria are not just power plants. For decades, biology textbooks described them that way — organelles that convert food into ATP, full stop.

Your mitochondria are not just power plants. For decades, biology textbooks described them that way — organelles that convert food into ATP, full stop. But starting in 2001, researchers began finding something unexpected inside mitochondrial DNA: small open reading frames encoding bioactive peptides that travel through the cell, enter the nucleus, and reprogram gene expression. These mitochondrial-derived peptides (MDPs) do not just help produce energy. They regulate metabolism, fight oxidative stress, protect against cell death, and communicate with tissues throughout the body.

This matters because mitochondrial dysfunction sits at the center of aging. As you get older, your mitochondria accumulate damage, produce less ATP, generate more reactive oxygen species (ROS), and lose their ability to adapt to stress. The downstream effects touch nearly every organ system — metabolic syndrome, neurodegeneration, cardiovascular disease, sarcopenia, and chronic fatigue all have mitochondrial roots.

The peptides covered in this guide — MOTS-c, humanin, SS-31 (elamipretide), and several others — each target mitochondrial health through different mechanisms. Some are produced naturally by your own mitochondria and decline with age. Others are synthetic molecules designed to reach the inner mitochondrial membrane and repair it from the inside. Together, they represent a new way of thinking about how to support the organelles that keep you alive.

None of these peptides are FDA-approved for general mitochondrial support. Some have advanced into clinical trials. Others remain entirely preclinical. This guide covers what the science actually shows.

Table of Contents

Why Mitochondrial Health Matters

Every cell in your body (except mature red blood cells) contains mitochondria — anywhere from a few hundred to several thousand per cell. Heart muscle cells, neurons, and skeletal muscle fibers are especially dense with them. These organelles generate roughly 90% of your cellular energy through oxidative phosphorylation, a process that runs along the electron transport chain embedded in the inner mitochondrial membrane [1].

But mitochondria do more than make ATP. They regulate calcium signaling, control apoptosis (programmed cell death), produce heat, synthesize steroid hormones, and manage the balance between oxidative stress and antioxidant defense. When mitochondrial function declines, the effects cascade.

Here is what goes wrong with age:

Energy production drops. Mitochondrial ATP output decreases steadily after your 30s. Muscle cells produce less force. Neurons fire less efficiently. You feel it as fatigue that no amount of sleep fixes.

Oxidative damage accumulates. The electron transport chain leaks electrons that react with oxygen to form superoxide radicals. Young mitochondria manage this through antioxidant enzymes. Aging mitochondria lose that balance, and the resulting oxidative damage hits mitochondrial DNA especially hard — it lacks the protective histones that shield nuclear DNA [2].

Quality control breaks down. Healthy cells remove damaged mitochondria through a process called mitophagy and replace them through biogenesis. Both systems slow with age, leaving a growing population of dysfunctional mitochondria that produce less energy and more ROS.

Membrane integrity deteriorates. The inner mitochondrial membrane is rich in a unique phospholipid called cardiolipin, which is essential for electron transport chain function. Cardiolipin is highly susceptible to oxidative damage, and its loss is a hallmark of mitochondrial aging [3].

Researchers now describe these changes as a central driver of what we experience as aging. The peptides in this guide target different nodes of this decline.

Mitochondrial-Derived Peptides: Your Mitochondria's Own Signaling System

Before 2001, scientists assumed mitochondrial DNA encoded only 13 proteins, all components of the electron transport chain, plus ribosomal RNAs and transfer RNAs needed to make them. The mitochondrial genome was considered a simple, well-understood piece of biological machinery.

Then humanin was discovered, cloned from the surviving brain tissue of an Alzheimer's patient. It was encoded in a short open reading frame (sORF) within the mitochondrial 16S rRNA gene — a region nobody thought could produce functional proteins [4]. Fourteen years later, MOTS-c was identified in the 12S rRNA gene [5]. In between, six small humanin-like peptides (SHLPs 1-6) were found in the same 16S rRNA region as humanin [6].

These molecules, collectively called mitochondrial-derived peptides, represent a signaling system that mitochondria use to communicate with the nucleus, other organelles, and distant tissues. They circulate in the blood, making some of them true hormones — or "mitokines," as researchers now call them.

A comprehensive 2026 review in the International Journal of Peptide Research and Therapeutics described MDPs as "regulators of cellular stress resistance, metabolism, inflammation, and survival" that interact with major aging pathways including AMPK, mTOR, and the sirtuins [7]. The review positioned them as a new class of geroprotectors — molecules that protect against the biological processes of aging.

The consistent finding across all MDPs: their levels decline with age. That decline correlates with the metabolic, neurological, and cardiovascular deterioration that defines aging. Researchers are now asking whether restoring MDP levels could slow or reverse some of that decline.

MOTS-c: The Exercise Mimetic

MOTS-c is a 16-amino-acid peptide encoded by a sORF in the mitochondrial 12S rRNA gene. Discovered in 2015 by Changhan Lee and Pinchas Cohen at the University of Southern California, it was the first MDP shown to regulate whole-body metabolism [5].

How It Works

MOTS-c's primary mechanism runs through the folate-methionine cycle. The peptide inhibits this metabolic pathway, which raises intracellular levels of AICAR — an endogenous activator of AMP-activated protein kinase (AMPK). AMPK is the cell's master energy sensor, the same switch flipped by exercise, caloric restriction, and the diabetes drug metformin [8].

What makes MOTS-c unusual among MDPs is that it moves. Under metabolic stress — glucose deprivation, oxidative pressure, or exercise — MOTS-c translocates from the cytoplasm into the nucleus. There, it binds DNA alongside transcription factors and activates stress-response genes. This movement is AMPK-dependent: block AMPK, and MOTS-c stays put [9].

Key Research Findings

Exercise mimicry. Young men cycling to exhaustion showed a 12-fold increase in MOTS-c levels within skeletal muscle, along with a significant rise in circulating levels. In mice, MOTS-c injections improved running endurance in young, middle-aged, and old animals. Late-life treatment (starting at 23.5 months — roughly equivalent to a human in their 70s) improved physical capacity and healthspan [10].

Metabolic protection. Mice on a high-fat diet that received MOTS-c gained less weight, had lower fasting insulin, and showed improved glucose tolerance. The effect was not from reduced food intake — MOTS-c increased energy expenditure through heat production [5].

Insulin sensitization. MOTS-c improves insulin sensitivity in aging mice by increasing GLUT4 translocation in skeletal muscle — the same mechanism by which exercise improves blood sugar control [11].

Anti-inflammatory action. MOTS-c suppresses IL-1-beta and IL-6 in adipose tissue, reducing the chronic low-grade inflammation that drives metabolic disease [12].

Heart protection. A 2025 study in Frontiers in Physiology showed MOTS-c restored mitochondrial respiration in diabetic heart tissue, addressing the mitochondrial dysfunction that leads to heart failure in type 2 diabetes patients [13].

Clinical Status

CohBar Inc. developed a MOTS-c analog called CB4211 and tested it in early-phase trials for fatty liver disease and obesity. Initial results showed the analog was safe and hinted at improvements in liver fat and glucose levels. But no completed clinical trials of native MOTS-c exist in humans. WADA prohibits it as a metabolic modulator (AMPK activator).

Humanin: The Cellular Guardian

Humanin is the oldest known MDP — a 24-amino-acid peptide encoded in the mitochondrial 16S rRNA gene. It was discovered in 2001 when three independent research groups found it through completely different experiments: one screening for neuroprotective genes, one looking for BAX-binding proteins, and one searching for IGFBP-3 partners [4].

How It Works

Humanin operates through two parallel mechanisms.

Inside the cell, it blocks apoptosis by physically binding to pro-apoptotic proteins BAX, Bid, and BimEL — preventing them from reaching the mitochondrial membrane and triggering the cell death cascade [14].

Outside the cell, secreted humanin binds to cell-surface receptors. It activates the heterotrimeric receptor complex gp130/CNTFR/WSX-1, triggering the JAK2/STAT3 and PI3K/Akt survival pathways. It also binds FPRL1 and FPRL2 receptors, activating ERK signaling and calcium mobilization [15].

This dual mechanism — intracellular and extracellular — is unusual for a peptide of its size and gives humanin a broad protective reach.

Key Research Findings

Neuroprotection. Humanin protects neurons against amyloid-beta toxicity in vitro and prevents memory deficits caused by amyloid-beta injection in mice. A specific SNP in the humanin-coding region (rs2854128) is associated with lower circulating humanin levels and accelerated cognitive aging in a large human cohort [16].

Lifespan extension. In C. elegans, humanin overexpression increased lifespan through a mechanism dependent on daf-16/FOXO. In mice, twice-weekly treatment with the potent analog HNG (S14G-humanin) starting in middle age improved metabolic healthspan parameters and reduced inflammatory markers [17].

Metabolic benefits. HNG-treated mice had reduced visceral fat and increased lean body mass maintained for at least 10 months. Humanin also improves glucose metabolism and insulin sensitivity in animal models, positioning it as both a neuroprotective and metabolic peptide [17].

Centenarian connection. Children of centenarians — people with a genetic predisposition toward exceptional longevity — have significantly higher circulating humanin levels than age-matched controls. This correlation supports the idea that higher humanin levels confer protective benefits against age-related disease [18].

Cardiovascular protection. Research published in PMC demonstrates that humanin reduces oxidative damage and inflammation in cardiovascular tissue, countering the pathological mechanisms that drive heart disease [19].

Clinical Status

Humanin remains a research peptide with no FDA-approved applications and no completed human clinical trials. The potent analog HNG is the most commonly studied form in preclinical work.

SS-31 (Elamipretide): The Membrane Stabilizer

SS-31 stands apart from the other peptides in this guide. It is not a mitochondrial-derived peptide — it is a synthetic tetrapeptide designed to target the inner mitochondrial membrane from the outside. But it has advanced further toward the clinic than any other mitochondrial peptide, including FDA approval for one indication.

How It Works

SS-31 (D-Arg-Dmt-Lys-Phe-NH2) carries an alternating aromatic-cationic motif that drives it to the inner mitochondrial membrane with high specificity. Once there, it binds cardiolipin — the phospholipid essential for electron transport chain function. By stabilizing cardiolipin's interactions with respiratory chain complexes, SS-31 restores electron flow, reduces electron leak, and lowers ROS production [20].

It also improves ADP sensitivity in aging mitochondria by increasing ADP uptake through the adenine nucleotide translocator (ANT). This directly addresses one of the key deficits in old mitochondria: they respond sluggishly to energy demand [21].

Key Research Findings

Reversing mitochondrial aging. In aged mice, eight weeks of SS-31 treatment reversed energetic deficits in skeletal muscle mitochondria, improved resting and dynamic muscle function, and restored redox homeostasis — without increasing mitochondrial content. The existing mitochondria simply worked better [22].

Exercise tolerance. SS-31 improved exercise capacity in old mice to levels comparable with young animals. In cardiac tissue, it restored systolic function and reduced protein oxidation (S-glutathionylation) [21].

Barth syndrome. The FDA approved elamipretide (branded as a prescription drug) in September 2025 for Barth syndrome, a rare mitochondrial disorder caused by mutations in the tafazzin gene that lead to abnormal cardiolipin. In the extension trial, patients improved their six-minute walk distance by an average of 96.1 meters and showed improved cardiac stroke volume [23].

Broad preclinical protection. SS-31 has shown benefit in preclinical models of heart failure, Parkinson's disease, ischemia-reperfusion injury, kidney disease, and disuse atrophy. It protects multiple organ systems by targeting the same fundamental problem: cardiolipin damage and electron transport chain dysfunction [24].

Clinical Limitations

Despite the Barth syndrome approval, SS-31 has had mixed results in larger indications. The phase 3 MMPOWER-3 trial for primary mitochondrial myopathy did not meet its primary endpoint. Heart failure trials showed favorable trends but not definitive proof of efficacy. The challenge may lie in the heterogeneity of mitochondrial dysfunction across different diseases [24].

SHLPs: The Emerging Players

The small humanin-like peptides (SHLPs 1 through 6) are encoded in the same 16S rRNA region of mitochondrial DNA as humanin. While less studied than MOTS-c or humanin, early research reveals a range of biological activities [6].

SHLP2 is the most promising. It reduces apoptosis and ROS generation, improves mitochondrial metabolism, and functions as an insulin sensitizer. When administered systemically or directly into the brain of mice, SHLP2 protected against high-fat diet-induced obesity and improved insulin sensitivity. Its mechanism involves binding to chemokine receptor 7 (CXCR7) and activating POMC neurons in the hypothalamus to suppress food intake and promote thermogenesis [25].

SHLP3 shares some protective effects with humanin — it reduces ROS, promotes mitochondrial biogenesis, and supports adipocyte differentiation while downregulating inflammatory markers [6].

SHLP6 does the opposite. It promotes apoptosis rather than preventing it. This is not necessarily harmful — controlled apoptosis is essential for removing damaged cells, including potentially cancerous ones [6].

Like humanin, circulating SHLP2 levels decline with age. This age-dependent decline may contribute to the metabolic dysfunction that accumulates in later life.

A newer MDP called SHMOOSE, identified in 2022, is associated with brain and mitochondrial function but remains in the earliest stages of characterization [26].

Supporting Peptides for Mitochondrial Function

Several peptides that are not MDPs still support mitochondrial health through indirect mechanisms.

Epitalon activates telomerase and preserves telomere length. Research shows it also boosts antioxidant enzymes through Nrf2 activation, reduces oxidative damage markers, and preserves mitochondrial integrity [27]. By protecting the DNA-level determinants of cellular aging, epitalon supports the mitochondrial health that depends on intact cellular machinery.

GHK-Cu increases expression of antioxidant enzymes including superoxide dismutase (SOD) while decreasing TNF-alpha and IL-6 production through NF-kB blockade. These anti-inflammatory and antioxidant actions indirectly protect mitochondria from the oxidative damage that degrades their function over time [28].

BPC-157 demonstrates cytoprotective effects that include activation of antioxidant pathways (VEGFR2-Akt-eNOS and HO-1) that protect cells under hypoxic conditions — conditions that directly stress mitochondria [29].

Comparison Table: Mitochondrial Peptides at a Glance

PeptideTypeLengthPrimary MechanismKey BenefitsClinical Status
MOTS-cMDP (12S rRNA)16 aaAMPK activation via folate cycle inhibitionExercise mimicry, insulin sensitivity, anti-obesityAnalog in early trials; WADA-prohibited
HumaninMDP (16S rRNA)24 aaBAX/Bid binding + JAK2/STAT3 activationNeuroprotection, anti-apoptosis, lifespan extensionPreclinical only
SS-31Synthetic4 aaCardiolipin binding on inner membraneMembrane stabilization, ETC repair, muscle functionFDA-approved for Barth syndrome
SHLP2MDP (16S rRNA)~26 aaCXCR7 binding, ERK/STAT3 activationInsulin sensitization, anti-obesity, neuroprotectionPreclinical only
SHLP3MDP (16S rRNA)~26 aaMitochondrial biogenesis promotionROS reduction, anti-inflammatoryPreclinical only
EpitalonSynthetic4 aaTelomerase activation, Nrf2 signalingTelomere protection, antioxidant enzyme inductionPreclinical; limited case studies
GHK-CuEndogenous3 aa + CuGene expression modulation (32% of genome)SOD induction, NF-kB blockade, anti-inflammatoryTopical use; systemic research ongoing

How Mitochondrial Peptides Work Together

The peptides in this guide target different parts of the same problem. Understanding their complementary mechanisms explains why researchers are interested in combination approaches.

Energy metabolism: MOTS-c activates AMPK to increase fatty acid oxidation and glucose uptake. SS-31 repairs the electron transport chain from the membrane side. They address supply and demand from different angles.

Cell survival: Humanin blocks apoptosis. MOTS-c supports survival through AMPK-mediated stress resistance. Together, they create overlapping safety nets.

Oxidative stress management: SS-31 reduces ROS production at the source. GHK-Cu and epitalon boost antioxidant enzymes. Humanin and the SHLPs reduce downstream oxidative damage.

Inflammation control: MOTS-c suppresses IL-1-beta and IL-6. Humanin reduces inflammatory markers through JAK/STAT modulation. GHK-Cu blocks NF-kB. Chronic inflammation is a major driver of mitochondrial decline.

For more on combining peptides, see the Peptide Stacking Guide.

Lifestyle Factors That Support Mitochondrial Health

Peptides do not work in a vacuum. The same biological pathways they target respond to basic lifestyle factors.

Exercise is the single most powerful mitochondrial intervention. It activates AMPK (the same pathway MOTS-c targets), stimulates mitochondrial biogenesis through PGC-1-alpha, and increases endogenous MOTS-c production [10].

Cold exposure activates brown adipose tissue and mitochondrial uncoupling proteins, increasing mitochondrial activity.

Caloric restriction and time-restricted eating activate AMPK and sirtuins — the same longevity pathways MDPs interact with.

Sleep quality affects mitochondrial repair through autophagy and mitophagy — the processes that remove damaged mitochondria and replace them.

These fundamentals form the base. Peptides are tools that may accelerate what these habits provide. For a broader view, see the guide on Best Peptides for Anti-Aging and Longevity.

Frequently Asked Questions

What are mitochondrial-derived peptides?

Mitochondrial-derived peptides (MDPs) are small bioactive peptides encoded by short open reading frames within mitochondrial DNA. The known MDPs include humanin, MOTS-c, SHLPs 1-6, and SHMOOSE. They were discovered starting in 2001, and they represent a signaling system that mitochondria use to communicate with the rest of the cell and with distant tissues throughout the body.

Which mitochondrial peptide has the most clinical evidence?

SS-31 (elamipretide) is the only mitochondrial peptide with FDA approval — it was approved in September 2025 for Barth syndrome, a rare mitochondrial disorder. It has been tested in 18 human clinical trials across conditions including mitochondrial myopathy, heart failure, and kidney disease. MOTS-c has a synthetic analog (CB4211) that has reached early-phase human trials, but no native MOTS-c trial has been completed.

Do MOTS-c levels really decline with age?

Yes. Multiple studies have confirmed that circulating MOTS-c levels decrease with age in humans. The same pattern holds for humanin and SHLP2. This age-dependent decline correlates with metabolic deterioration, increased insulin resistance, and reduced physical performance. Interestingly, exercise increases endogenous MOTS-c production — one reason physical activity is considered the most effective natural intervention for mitochondrial health.

Can I take MOTS-c as a supplement?

MOTS-c is not an approved supplement or medication. It is sold as a research peptide, typically requiring subcutaneous injection. It is prohibited by WADA for athletes. No completed human clinical trials confirm its safety or efficacy at any dose. The research showing benefits has been conducted in mice and cell cultures.

How does SS-31 differ from antioxidant supplements?

Traditional antioxidants (vitamin C, vitamin E, CoQ10) scavenge free radicals after they are produced. SS-31 works upstream: by stabilizing cardiolipin and restoring electron transport chain function, it reduces the production of free radicals at their source. This targeted approach avoids the potential problem of systemic antioxidant supplementation, which can interfere with beneficial ROS signaling (like the oxidative stress signals that drive exercise adaptations).

Significantly. Mitochondrial dysfunction is one of the nine hallmarks of aging, and MDPs directly address it. Humanin has extended lifespan in C. elegans and improved healthspan in mice. MOTS-c improves physical capacity and metabolic health in aging animals. Epitalon, while not an MDP, protects telomeres — another hallmark of aging — and also supports mitochondrial integrity. These peptides overlap heavily with the longevity peptide category.

What is the connection between mitochondrial peptides and inflammation?

Damaged mitochondria release damage-associated molecular patterns (DAMPs) that activate the innate immune system, driving the chronic low-grade inflammation of aging. MDPs like MOTS-c and humanin reduce inflammatory cytokines directly. SS-31 reduces inflammation indirectly by preventing the mitochondrial damage that triggers the inflammatory response.

The Bottom Line

Mitochondrial peptides are not a category you would have found in a pharmacology textbook twenty years ago. The discovery that mitochondria produce their own signaling molecules — and that those molecules decline with age in ways that mirror the decline of the organism itself — has opened a new research front in aging biology.

MOTS-c mimics exercise at the molecular level. Humanin blocks cell death through mechanisms no other molecule in the body replicates. SS-31 has reached the clinic, with an FDA approval that validates the therapeutic potential of targeting the inner mitochondrial membrane. The SHLPs and other MDPs are still early in their research arc but already show distinct biological activities.

The science is real. The caution is also real. Outside of SS-31's narrow Barth syndrome indication, none of these peptides have proven safe and effective in humans through the kind of rigorous trials that justify clinical use. The gap between a compelling mouse study and a validated human therapy is wide, and many promising molecules have fallen into it.

What is not in question is the biology. Mitochondrial health determines cellular health, and cellular health determines how well you age. Supporting that biology — through exercise, through metabolic discipline, and possibly through peptides as the evidence matures — is one of the more grounded strategies for extending healthspan.

References

  1. Nunnari, J., & Suomalainen, A. (2012). Mitochondria: In sickness and in health. Cell, 148(6), 1145-1159. PubMed

  2. Balaban, R. S., Nemoto, S., & Finkel, T. (2005). Mitochondria, oxidants, and aging. Cell, 120(4), 483-495. PubMed

  3. Paradies, G., et al. (2010). Role of cardiolipin peroxidation and mitochondrial dysfunction in cardiovascular diseases. Drug Metabolism Reviews, 42(3), 558-563. PubMed

  4. Hashimoto, Y., et al. (2001). A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. PNAS, 98(11), 6336-6341. PubMed

  5. Lee, C., et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 21(3), 443-454. Cell Press

  6. Cobb, L. J., et al. (2016). Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Aging, 8(4), 796-809. PubMed

  7. Mitochondrial Derived Peptides (MDPs) as Emerging Gero Protectors: Molecular Signaling, Systemic Effects, and Translational Perspectives. (2026). International Journal of Peptide Research and Therapeutics, 32. Springer

  8. Kim, S. J., et al. (2019). The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiological Reports, 7(13), e14171. Wiley

  9. Kim, K. H., et al. (2018). MOTS-c: an equal opportunity insulin sensitizer. Journal of Molecular Medicine, 97, 487-490. PMC

  10. Reynolds, J. C., et al. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 12(1), 470. Nature

  11. Kim, S. J., et al. (2019). The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiological Reports, 7(13). PubMed

  12. Lu, H., et al. (2023). Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. Journal of Translational Medicine, 21, 36. Springer

  13. MOTS-c restores mitochondrial respiration in type 2 diabetic heart. (2025). Frontiers in Physiology, 16. Frontiers

  14. Guo, B., et al. (2003). Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature, 423(6938), 456-461. PubMed

  15. Yen, K., et al. (2020). The mitochondrial derived peptide humanin activates the ERK1/2, AKT, and STAT3 signaling pathways. Oncotarget, 11(13), 1129-1144. Oncotarget

  16. Yen, K., et al. (2018). Humanin prevents age-related cognitive decline in mice and is associated with improved cognitive age in humans. Scientific Reports, 8, 14212. Nature

  17. Muzumdar, R. H., et al. (2020). The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan. Aging, 12(12), 11185-11199. PMC

  18. Yen, K., et al. (2020). The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan. Aging, 12(12), 11185-11199. Aging

  19. Mitochondria-derived peptides: Promising microproteins in cardiovascular diseases (Review). (2025). PMC. PMC

  20. Birk, A. V., et al. (2014). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology, 24(8), 1250-1261. PubMed

  21. Siegel, M. P., et al. (2023). The mitochondrially targeted peptide elamipretide (SS-31) improves ADP sensitivity in aged mitochondria by increasing uptake through the adenine nucleotide translocator (ANT). GeroScience, 45, 3531-3541. PubMed

  22. Siegel, M. P., et al. (2013). Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell, 12(5), 763-771. PMC

  23. FDA approves drug for treatment of rare mitochondrial disorder. (2025). Johns Hopkins Hub. JHU

  24. Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects. (2025). Biomedicine & Pharmacotherapy. ScienceDirect

  25. Cobb, L. J., et al. (2016). Naturally occurring mitochondrial-derived peptides are age-dependent regulators. Aging, 8(4), 796-809. Aging

  26. Miller, B., et al. (2022). SHMOOSE, a mitochondrial-derived peptide. Molecular Psychiatry, 28, 1382-1395. PubMed

  27. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. (2025). Biogerontology. Springer

  28. Pickart, L., & Margolina, A. (2018). The effect of the human plasma molecule GHK-Cu on stem cell actions and expression of relevant genes. OBM Geriatrics, 2(3). Lidsen

  29. Multifunctionality and Possible Medical Application of the BPC 157 Peptide. (2025). Pharmaceuticals, 18(2), 185. PMC